NSW2031 - Randwick - Scientia Clinical Research Ltd (COMPLETED)2065 - St Leonards - GenesisCare North Shore Private Hospital (COMPLETED)2109 - North Ryde - Macquarie University Hospital (COMPLETED)2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)2170 - Liverpool - Sydney South West Private Hospital (COMPLETED)2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (COMPLETED)

VIC3199 - Frankston - Peninsula Health Frankston Hospital (COMPLETED)

QLD4215 - Southport - Gold Coast Private Hospital (COMPLETED)

WA6009 - Nedlands - One Clinical Research (COMPLETED)

NCT05176483

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)

NCT05150691

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors (DB-1303-O-1001)

NCT05086692

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (ABILITY-1)

NCT04879329

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2 (RC48G001)

NCT03486873

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (3475-587)

2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (COMPLETED)

4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)4120 - Greenslopes - Greenslopes Private Hospital (COMPLETED)

NCT02582697

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)

3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)

NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)

ACTRN12626000289314

A Phase 1b, open-label, non-randomised, multicentre dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AXA-042 monotherapy in subjects with advanced solid tumours.

NCT06199908

First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors (AMT-562-01)

NCT05483530

A Phase 1 Clinical Study to Investigate the Safety, Tolerability and Efficacy of HLX60 (Anti-GARP Monoclonal Antibody) Combination With HLX10 (Anti-PD-1 Monoclonal Antibody) in Subjects With Advanced or Metastatic Solid Tumors (HLX60HLX10-FIH101)

PD-1/PD-L1	30%
PD-1	25%
androgen axis	11%
ERBB2	11%
EGFR	10%
MET	10%
AR	10%
oestrogen axis	8%
VEGFR2	7%
ER	7%
CYP17A1	7%
KRAS	6%
AXL	6%
VEGF	6%
Trop2	6%
CDK4	6%
Nectin4	5%
PD-L1	5%
CDK6	5%
ERBB3	5%
PARP	5%
B7H3	5%
CYP11A1	5%
HIF2a	4%
MER	4%
CTLA4	4%
KIT	4%
RET	4%
ROS1	4%
VEGFR	4%
CD44v9	2%
VEGFA	2%
FGFR	2%
FGFR3	2%
PI3Kalpha	2%
PSMA	2%
B7H4	2%
CDK4 selective	2%
SMO	2%
LAG3	2%
HDAC	1%
CD70	1%
CCR8	1%
AR	1%
ITGB6	1%
4-1BB	1%
p95ERBB2	1%
HRAS G12C	1%
NRAS G12C	1%
FGFR2	1%
FGFR2b	1%
TF	1%
ER alpha	1%
CDH17	1%
PARP1-selective	1%
HPK1	1%
CD47	1%
MUC18	1%
ERK	1%
DNA-dependent protein kinase	1%
CDK2	1%
KLK2	1%
mTOR	1%
mTORC1	1%
CLDN18.2	1%
IL-2	1%
TLR2/TLR6	1%
GARP	1%

ARTICANZ - Beta (ver 0.91)

Search results

Filters